<DOC>
	<DOCNO>NCT01783015</DOCNO>
	<brief_summary>The first 12 week study compare efficacy etanercept 50 mg once-weekly placebo subject rheumatoid arthritis respond well infliximab adalimumab plus methotrexate . This comparison perform subject separately subject anti-drug antibody positive one medication . From week 12 week 24 , subject receive etanercept 50 mg once-weekly . The effect anti-drug antibody status efficacy etanercept well safety profile etanercept subject also evaluate throughout study .</brief_summary>
	<brief_title>Study Etanercept Subjects With Rheumatoid Arthritis Who Have Had Inadequate Response Adalimumab Infliximab Plus Methotrexate</brief_title>
	<detailed_description>This study prematurely terminate June 25 , 2014 due significant continue delay achieve study B1801355 enrolment target . The decision stop study driven safety concern .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Met 1987 ACR Revised Criteria RA 2 . A history inadequate response infliximab adalimumab combination methotrexate . 3 . A stable dose oral methotrexate least 6 week baseline visit . 1 . ACR functional class IV 2 . Prior treatment etanercept ; infliximab adalimumab ; immunosuppressive biologic agent infliximab adalimumab . 3 . Discontinuation infliximab adalimumab primary reason inadequate efficacy response .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>etanercept</keyword>
	<keyword>methotrexate</keyword>
	<keyword>infliximab</keyword>
	<keyword>adalimumab</keyword>
	<keyword>anti-drug antibody</keyword>
</DOC>